386 related articles for article (PubMed ID: 31606273)
1. Distinct Binding Preferences between Ras and Raf Family Members and the Impact on Oncogenic Ras Signaling.
Terrell EM; Durrant DE; Ritt DA; Sealover NE; Sheffels E; Spencer-Smith R; Esposito D; Zhou Y; Hancock JF; Kortum RL; Morrison DK
Mol Cell; 2019 Dec; 76(6):872-884.e5. PubMed ID: 31606273
[TBL] [Abstract][Full Text] [Related]
2. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of C-RAF:KSR1 complex by DiRas3 reduces availability of C-RAF for dimerization with B-RAF.
Baljuls A; Dobrzyński M; Rauch J; Rauch N; Kolch W
Cell Signal; 2016 Oct; 28(10):1451-62. PubMed ID: 27368419
[TBL] [Abstract][Full Text] [Related]
4. C-Raf is required for the initiation of lung cancer by K-Ras(G12D).
Karreth FA; Frese KK; DeNicola GM; Baccarini M; Tuveson DA
Cancer Discov; 2011 Jul; 1(2):128-36. PubMed ID: 22043453
[TBL] [Abstract][Full Text] [Related]
5. ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold.
Posada IM; Serulla M; Zhou Y; Oetken-Lindholm C; Abankwa D; Lectez B
PLoS One; 2016; 11(7):e0159677. PubMed ID: 27437940
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-β-stimulated clone-22 is a negative-feedback regulator of Ras / Raf signaling: Implications for tumorigenesis.
Nakamura M; Kitaura J; Enomoto Y; Lu Y; Nishimura K; Isobe M; Ozaki K; Komeno Y; Nakahara F; Oki T; Kume H; Homma Y; Kitamura T
Cancer Sci; 2012 Jan; 103(1):26-33. PubMed ID: 21943131
[TBL] [Abstract][Full Text] [Related]
7. A Structure is Worth a Thousand Words: New Insights for RAS and RAF Regulation.
Simanshu DK; Morrison DK
Cancer Discov; 2022 Apr; 12(4):899-912. PubMed ID: 35046094
[TBL] [Abstract][Full Text] [Related]
8. Ornithine decarboxylase induction in transformation by H-Ras and RhoA.
Shantz LM; Pegg AE
Cancer Res; 1998 Jul; 58(13):2748-53. PubMed ID: 9661886
[TBL] [Abstract][Full Text] [Related]
9. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.
Garnett MJ; Rana S; Paterson H; Barford D; Marais R
Mol Cell; 2005 Dec; 20(6):963-9. PubMed ID: 16364920
[TBL] [Abstract][Full Text] [Related]
10. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
[TBL] [Abstract][Full Text] [Related]
11. Elimination of B-RAF in oncogenic C-RAF-expressing alveolar epithelial type II cells reduces MAPK signal intensity and lung tumor growth.
Zanucco E; El-Nikhely N; Götz R; Weidmann K; Pfeiffer V; Savai R; Seeger W; Ullrich A; Rapp UR
J Biol Chem; 2014 Sep; 289(39):26804-26816. PubMed ID: 25096573
[TBL] [Abstract][Full Text] [Related]
12. Is Nanoclustering essential for all oncogenic KRas pathways? Can it explain why wild-type KRas can inhibit its oncogenic variant?
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():114-120. PubMed ID: 29307569
[TBL] [Abstract][Full Text] [Related]
13. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis.
DeNicola GM; Karreth FA; Humpton TJ; Gopinathan A; Wei C; Frese K; Mangal D; Yu KH; Yeo CJ; Calhoun ES; Scrimieri F; Winter JM; Hruban RH; Iacobuzio-Donahue C; Kern SE; Blair IA; Tuveson DA
Nature; 2011 Jul; 475(7354):106-9. PubMed ID: 21734707
[TBL] [Abstract][Full Text] [Related]
14. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Shao W; Mishina YM; Feng Y; Caponigro G; Cooke VG; Rivera S; Wang Y; Shen F; Korn JM; Mathews Griner LA; Nishiguchi G; Rico A; Tellew J; Haling JR; Aversa R; Polyakov V; Zang R; Hekmat-Nejad M; Amiri P; Singh M; Keen N; Dillon MP; Lees E; Ramurthy S; Sellers WR; Stuart DD
Cancer Res; 2018 Mar; 78(6):1537-1548. PubMed ID: 29343524
[TBL] [Abstract][Full Text] [Related]
15. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.
Ritt DA; Monson DM; Specht SI; Morrison DK
Mol Cell Biol; 2010 Feb; 30(3):806-19. PubMed ID: 19933846
[TBL] [Abstract][Full Text] [Related]
16. Ras-related tumorigenesis is suppressed by BNIP3-mediated autophagy through inhibition of cell proliferation.
Wu SY; Lan SH; Cheng DE; Chen WK; Shen CH; Lee YR; Zuchini R; Liu HS
Neoplasia; 2011 Dec; 13(12):1171-82. PubMed ID: 22241963
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic K-Ras4B Dimerization Enhances Downstream Mitogen-activated Protein Kinase Signaling.
Muratcioglu S; Aydin C; Odabasi E; Ozdemir ES; Firat-Karalar EN; Jang H; Tsai CJ; Nussinov R; Kavakli IH; Gursoy A; Keskin O
J Mol Biol; 2020 Feb; 432(4):1199-1215. PubMed ID: 31931009
[TBL] [Abstract][Full Text] [Related]
18. Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.
Ikenoue T; Hikiba Y; Kanai F; Aragaki J; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Matsumura M; Kawabe T; Omata M
Cancer Res; 2004 May; 64(10):3428-35. PubMed ID: 15150094
[TBL] [Abstract][Full Text] [Related]
19. Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
Kern F; Doma E; Rupp C; Niault T; Baccarini M
Oncogene; 2013 May; 32(19):2483-92. PubMed ID: 22733131
[TBL] [Abstract][Full Text] [Related]
20. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
